Actively Recruiting
Ate-Bev Early Response Prediction Model in Advanced HCC
Led by Seoul National University Hospital · Updated on 2025-05-15
170
Participants Needed
1
Research Sites
231 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.
CONDITIONS
Official Title
Ate-Bev Early Response Prediction Model in Advanced HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with advanced hepatocellular carcinoma and planned to receive atezolizumab-bevacizumab as first-line therapy
- Willing to participate in the study
You will not qualify if you...
- History of severe allergy to contrast agents
- Severe other health problems as defined by American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Hospital
Seoul, South Korea
Actively Recruiting
Research Team
J
Jeong-Hoon Lee, MD PhD
CONTACT
H
Hyunjae Shin, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here